(Q41178007)

27 September 2017

1 reference

title

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia (English)

1 reference

27 September 2017

0 references

G L Plosker

1

1 reference

27 September 2017

A J Wagstaff

series ordinal

2

1 reference

27 September 2017

publication date

1 March 1996

1 reference

27 September 2017

number of pages

27

1 reference

inferred from page(s)

published in

Drugs

1 reference

27 September 2017

volume

51

1 reference

27 September 2017

issue

3

1 reference

27 September 2017

page(s)

433-459

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199651030-00011

27 September 2017

exact match

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy

1 reference

12 December 2020

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin

1 reference

12 December 2020

Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors

1 reference

12 December 2020

Lovastatin. Warfarin interaction

1 reference

12 December 2020

Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.

1 reference

12 December 2020

Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.

1 reference

12 December 2020

Cost-effectiveness of combined statin-resin therapy

1 reference

12 December 2020

Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group

1 reference

12 December 2020

Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group

1 reference

12 December 2020

Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study Group

1 reference

12 December 2020

Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans

1 reference

12 December 2020

Economics of lipid lowering with HMG CoA reductase inhibitors

1 reference

12 December 2020

A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.

1 reference

12 December 2020

Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database

1 reference

12 December 2020

Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial

1 reference

12 December 2020

Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin

1 reference

12 December 2020

Clinical pharmacokinetics and practical applications of simvastatin

1 reference

12 December 2020

Binding of fluvastatin to blood cells and plasma proteins

1 reference

12 December 2020

Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation

1 reference

12 December 2020

Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia

1 reference

12 December 2020

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin

1 reference

12 December 2020

Change in cholesterol awareness and action. Results from national physician and public surveys

1 reference

12 December 2020

Fluvastatin with and without niacin for hypercholesterolemia

1 reference

12 December 2020

Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy

1 reference

12 December 2020

Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin

1 reference

12 December 2020

Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia

1 reference

12 December 2020

Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative

1 reference

12 December 2020

Biotransformation of fluvastatin sodium in humans

1 reference

12 December 2020

Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes

1 reference

12 December 2020

Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia

1 reference

12 December 2020

1 reference

12 December 2020

Health and economic issues in theprevention of coronary artery disease

1 reference

12 December 2020

Long-term experience with pravastatin in clinical research trials

1 reference

12 December 2020

The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia

1 reference

12 December 2020

Updated clinical safety experience with fluvastatin

1 reference

12 December 2020

Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group

1 reference

12 December 2020

Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

12 December 2020

Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers

1 reference

12 December 2020

Simvastatin: the clinical profile

1 reference

12 December 2020

Long-term safety and efficacy profile of simvastatin

1 reference

12 December 2020

Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease

1 reference

12 December 2020

Clinical implications of the biopharmaceutical properties of fluvastatin

1 reference

12 December 2020

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination

1 reference

12 December 2020

Effects of simvastatin on serum lipids and atherosclerosis in WHHL rabbits

1 reference

12 December 2020

Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients

1 reference

12 December 2020

Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors

1 reference

12 December 2020

Pharmacokinetics of fluvastatin and specific drug interactions

1 reference

12 December 2020

Effects of alcohol and fluvastatin on lipid metabolism and hepatic function

1 reference

12 December 2020

Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit

1 reference

12 December 2020

HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits

1 reference

12 December 2020

Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells

1 reference

12 December 2020

Epidemiology of hypercholesterolemia and European management guidelines

1 reference

12 December 2020

Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. In vivo study using low density lipoprotein receptor deficient watanabe heritable hyperlipidemic rabbits

1 reference

12 December 2020

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine

1 reference

12 December 2020

Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia

1 reference

12 December 2020

Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods.

1 reference

12 December 2020

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

1 reference

12 December 2020

Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study. French-Dutch Fluvastatin Study Group.

1 reference

12 December 2020

Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment

1 reference

12 December 2020

Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate

1 reference

12 December 2020

Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase

1 reference

12 December 2020

Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

12 December 2020

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats

1 reference

12 December 2020

Fluvastatin in severe hypercholesterolemia:Analysis of a clinical trial database

1 reference

12 December 2020

Low-dose lovastatin safely lowers cholesterol after cardiac transplantation

1 reference

12 December 2020

Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group

1 reference

12 December 2020

Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients

1 reference

12 December 2020

Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women

1 reference

12 December 2020

Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits

1 reference

12 December 2020

A review of clinical trials comparing HMG-CoA reductase inhibitors

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias

1 reference

12 December 2020

A Randomized Multicenter Trial Comparing and Efficacy of Simvastatin and Fluvastatin

1 reference

12 December 2020

Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety.

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Safety and tolerability of fluvastatin with concomitant use of antihypertensive agents. An analysis of a clinical trial database

1 reference

12 December 2020

Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group

1 reference

12 December 2020

Lack of interaction between fluvastatin andoral nypoylycemie agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.

1 reference

12 December 2020

Efficacy and safety of fluvastatin in women with primary hypercholesterolaemia

1 reference

12 December 2020

Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation

1 reference

12 December 2020

Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety

1 reference

12 December 2020

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

12 December 2020

The interaction of fluvastatin and cyclosporin A in renal transplant patients

1 reference

12 December 2020

Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.

1 reference

12 December 2020

Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association

1 reference

12 December 2020

Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia

1 reference

12 December 2020

10.2165/00003495-199651030-00011

Identifiers

DOI

1 reference

Dimensions Publication ID

27 September 2017

1004937618

0 references

1 reference